AR089114A1 - PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3 - Google Patents
PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3Info
- Publication number
- AR089114A1 AR089114A1 ARP120104599A ARP120104599A AR089114A1 AR 089114 A1 AR089114 A1 AR 089114A1 AR P120104599 A ARP120104599 A AR P120104599A AR P120104599 A ARP120104599 A AR P120104599A AR 089114 A1 AR089114 A1 AR 089114A1
- Authority
- AR
- Argentina
- Prior art keywords
- epcamxcd3
- adverse effects
- prevention
- bispecific antibodies
- effects caused
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Un glucocorticoide (GC) que puede usarse en la mejora, el tratamiento y/o la profilaxis de los efectos adversos hepáticos y/o gastroenterológicos que son causados por el anticuerpo biespecífico EpCAMxCD3, donde la administración del GC se inicia antes de la administración del anticuerpo biespecífico EpCAMxCD3. Conjuntos de elementos que comprenden un GC, un anticuerpo biespecífico EpCAMxCD3 e instrucciones de uso donde se indica que el GC ha de emplearse en el tratamiento, la mejora y/o la profilaxis de los efectos adversos hepáticos y/o gastroenterológicos que son causados por el anticuerpo biespecífico EpCAMxCD3 en un paciente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569180P | 2011-12-09 | 2011-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089114A1 true AR089114A1 (es) | 2014-07-30 |
Family
ID=47520027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104599A AR089114A1 (es) | 2011-12-09 | 2012-12-07 | PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3 |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR089114A1 (es) |
| AU (1) | AU2012350429A1 (es) |
| TW (1) | TW201322985A (es) |
| UY (1) | UY34504A (es) |
| WO (1) | WO2013083809A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2417065T3 (es) | 2005-04-26 | 2013-08-05 | Trion Pharma Gmbh | Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer |
| EA202090931A3 (ru) | 2015-05-18 | 2020-10-30 | Тср2 Терапьютикс Инк. | Композиции и способы перепрограммирования tcr с помощью гибридных белков |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| KR102771251B1 (ko) | 2017-09-08 | 2025-02-24 | 다케다 야쿠힌 고교 가부시키가이샤 | 제약된 조건적으로 활성화된 결합 단백질 |
| JP2022524338A (ja) | 2019-03-05 | 2022-05-02 | 武田薬品工業株式会社 | 拘束され、条件的に活性化された結合タンパク質 |
| WO2023044039A1 (en) * | 2021-09-16 | 2023-03-23 | TCR2 Therapeutics Inc. | Compositions and methods for treating cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
| US7919089B2 (en) | 2003-05-31 | 2011-04-05 | Micromet Ag | Pharmaceutical composition comprising a bispecific antibody for EpCAM |
| US8076459B2 (en) | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| ES2417065T3 (es) * | 2005-04-26 | 2013-08-05 | Trion Pharma Gmbh | Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer |
| RS58217B1 (sr) | 2007-04-03 | 2019-03-29 | Amgen Res Munich Gmbh | Interspecijski specifičan vezujući domen |
| EP2155788B1 (en) | 2007-04-03 | 2012-06-27 | Micromet AG | Cross-species-specific bispecific binders |
| NZ591087A (en) | 2008-10-01 | 2012-08-31 | Micromet Ag | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| SG179027A1 (en) | 2009-09-18 | 2012-04-27 | Micromet Ag | Dosage regimen for administering an epcamxcd3 bispecific antibody |
-
2012
- 2012-12-07 AU AU2012350429A patent/AU2012350429A1/en not_active Abandoned
- 2012-12-07 WO PCT/EP2012/074855 patent/WO2013083809A1/en not_active Ceased
- 2012-12-07 UY UY0001034504A patent/UY34504A/es not_active Application Discontinuation
- 2012-12-07 AR ARP120104599A patent/AR089114A1/es not_active Application Discontinuation
- 2012-12-10 TW TW101146446A patent/TW201322985A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201322985A (zh) | 2013-06-16 |
| UY34504A (es) | 2013-06-28 |
| AU2012350429A1 (en) | 2013-07-11 |
| WO2013083809A1 (en) | 2013-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121076T1 (el) | Τρικυκλικες ενωσεις ως αντικαρκινικοι παραγοντες | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| MX2016003216A (es) | Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b. | |
| CL2013003019A1 (es) | Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih. | |
| GT201400136A (es) | Compuestos y métodos de benzaldehído substituído para su uso en incrementar la oxigenación de los tejidos | |
| CR20140405A (es) | Apoptosis señal reguladores del inhibidor de quinasa | |
| ECSP13013074A (es) | Nuevos derivados de piridina | |
| MX2015009105A (es) | Composiciones en solucion solida y su uso en inflamacion cronica. | |
| NI201500077A (es) | Novedosos derivados de bencimidazol como antagonistas de ep4 | |
| CR20140493A (es) | Compuestos novedosos | |
| UY35210A (es) | Inhibidores de autotaxina | |
| CR20130671A (es) | Antagonistas de trpv4 | |
| CR20150250A (es) | Nuevos derivados de piridina | |
| CR20140113A (es) | Imidazopiridazinas sustituidas con amino | |
| CR20150447A (es) | Nuevos derivados de pirazol | |
| CR20150204A (es) | Nuevos derivados de piridina | |
| CR20150440A (es) | Nuevos derivados de piridina | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| CR20160433A (es) | Nuevos compuestos | |
| SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| AR089114A1 (es) | PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3 | |
| UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
| ECSP14002542A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
| DOP2016000118A (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
| DOP2016000007A (es) | Pirazolpiridinas sustituidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |